Baseline characteristics of 3350 patients with R/R LBCL treated with CD19 CAR T-cell therapy in this cohort
| Parameters . | N = 3350 (%) . |
|---|---|
| Median age at the time of CAR T-cell therapy, y (IQR) | 62.5 (53.8-69.4) |
| Age ≥60 y at the time of CAR T-cell therapy, n (%) | 1958 (58.4) |
| Male sex, n (%) | 2104 (62.9) |
| Race, n (%) | |
| Caucasian | 2646 (79.0) |
| African American | 183 (5.5) |
| Asian | 161 (4.8) |
| Native American and Pacific Islander | 24 (0.7) |
| Mixed | 15 (0.4) |
| HCT-CI, n (%) | |
| 1-2 | 1157 (34.5) |
| 3-4 | 757 (22.6) |
| 5 or more | 293 (8.7) |
| Missing | 171 (5.1) |
| Diagnostic indication of CD19 CAR T-cell therapy, n (%) | |
| Diffuse large B-cell lymphoma | 3241 (96.7) |
| High-grade B-cell lymphoma | 80 (2.4) |
| Other | 29 (0.9) |
| Transformed lymphoma, n (%) | |
| Transformed | 925 (27.6) |
| De novo | 2340 (69.9) |
| Missing/Unknown | 85 (2.5) |
| Previous lines of treatment before CAR T-cell therapy, n (%) | |
| 1-3 | 2030 (60.6) |
| 4 or more lines | 1222 (36.5) |
| Missing | 98 (2.9) |
| Previous HCT before CAR T-cell therapy, n (%) | 865 (25.8) |
| Median time from HCT to CAR T-cell therapy (IQR), mo | 13.4 (7.2-28.2) |
| Disease status at the time of CAR T-cell therapy, n (%) | |
| Chemosensitive relapse, complete remission | 140 (4.2) |
| Chemosensitive relapse, partial remission | 688 (20.5) |
| Chemoresistant relapse | 2175 (64.9) |
| Relapse, untreated | 197 (5.9) |
| Unknown | 150 (4.5) |
| KPS, n (%) | |
| 90-100 | 1361 (40.6) |
| 80 | 991 (29.6) |
| <80 | 640 (19.1) |
| Missing | 358 (10.7) |
| Receipt of bridging therapy, n (%) | |
| No | 2451 (73.2) |
| Yes | 801 (23.9) |
| Missing | 98 (2.9) |
| History of infection before CAR T-cell therapy, n (%) | 133 (4.0) |
| Parameters . | N = 3350 (%) . |
|---|---|
| Median age at the time of CAR T-cell therapy, y (IQR) | 62.5 (53.8-69.4) |
| Age ≥60 y at the time of CAR T-cell therapy, n (%) | 1958 (58.4) |
| Male sex, n (%) | 2104 (62.9) |
| Race, n (%) | |
| Caucasian | 2646 (79.0) |
| African American | 183 (5.5) |
| Asian | 161 (4.8) |
| Native American and Pacific Islander | 24 (0.7) |
| Mixed | 15 (0.4) |
| HCT-CI, n (%) | |
| 1-2 | 1157 (34.5) |
| 3-4 | 757 (22.6) |
| 5 or more | 293 (8.7) |
| Missing | 171 (5.1) |
| Diagnostic indication of CD19 CAR T-cell therapy, n (%) | |
| Diffuse large B-cell lymphoma | 3241 (96.7) |
| High-grade B-cell lymphoma | 80 (2.4) |
| Other | 29 (0.9) |
| Transformed lymphoma, n (%) | |
| Transformed | 925 (27.6) |
| De novo | 2340 (69.9) |
| Missing/Unknown | 85 (2.5) |
| Previous lines of treatment before CAR T-cell therapy, n (%) | |
| 1-3 | 2030 (60.6) |
| 4 or more lines | 1222 (36.5) |
| Missing | 98 (2.9) |
| Previous HCT before CAR T-cell therapy, n (%) | 865 (25.8) |
| Median time from HCT to CAR T-cell therapy (IQR), mo | 13.4 (7.2-28.2) |
| Disease status at the time of CAR T-cell therapy, n (%) | |
| Chemosensitive relapse, complete remission | 140 (4.2) |
| Chemosensitive relapse, partial remission | 688 (20.5) |
| Chemoresistant relapse | 2175 (64.9) |
| Relapse, untreated | 197 (5.9) |
| Unknown | 150 (4.5) |
| KPS, n (%) | |
| 90-100 | 1361 (40.6) |
| 80 | 991 (29.6) |
| <80 | 640 (19.1) |
| Missing | 358 (10.7) |
| Receipt of bridging therapy, n (%) | |
| No | 2451 (73.2) |
| Yes | 801 (23.9) |
| Missing | 98 (2.9) |
| History of infection before CAR T-cell therapy, n (%) | 133 (4.0) |